Practical management of bevacizumab-related toxicities in glioblastoma

Oncologist

Volumn 20, Issue 2, 2015, Pages 166-175

  Brandes, Alba A ^a   Bartolotti, Marco ^a   Tosoni, Alicia ^a   Poggi, Rosalba ^a   Franceschi, Enrico ^a  

^a BELLARIA HOSPITAL   (Italy)

Author keywords

Antiangiogenic; Bevacizumab; Side effects; Toxicity

Indexed keywords

BEVACIZUMAB; ENZASTAURIN; HEPARAN SULFATE; LOW MOLECULAR WEIGHT HEPARIN; MESALAZINE; PROBIOTIC AGENT; RIFAXIMIN; TANDUTINIB; TEMOZOLOMIDE; THROMBOMODULIN; VASCULOTROPIN; ANGIOGENESIS INHIBITOR;

ARTERIAL THROMBOEMBOLISM; ARTICLE; BLEEDING; BLOOD PRESSURE MONITORING; BRAIN HEMORRHAGE; BREAST CANCER; CARCINOMATOSIS; CLINICAL TRIAL (TOPIC); COLITIS; COLON ADENOCARCINOMA; DIGESTIVE SYSTEM PERFORATION; DIVERTICULITIS; GLIOBLASTOMA; HUMAN; HYPERTENSION; INCIDENCE; INTESTINE OBSTRUCTION; META ANALYSIS (TOPIC); NON SMALL CELL LUNG CANCER; OVARY CANCER; PANCREAS CANCER; PEPTIC ULCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TUMOR NECROSIS; VENOUS THROMBOEMBOLISM; WOUND HEALING; CHEMICALLY INDUCED; DISEASE MANAGEMENT; PATHOLOGY;

ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DISEASE MANAGEMENT; GLIOBLASTOMA; HUMANS; VENOUS THROMBOEMBOLISM;

EID: 84922694046     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0330     Document Type: Article

References (53)

1. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl JMed 2004;350:2335-2342.
2. Sandler A, Gray R, Perry MC et al. Paclitaxelcarboplatin alone or with bevacizumab for nonsmall-cell lung cancer. N Engl J Med 2006;355: 2542-2550.
3. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007;370: 2103-2111.
4. Perren TJ, Swart AM, Pfisterer J et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl JMed 2011;365:2484-2496.
5. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-1544.
6. Reck M, von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-1234.
7. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl JMed 2007;357:2666-2676.
8. Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-4740.
9. Reardon DA, Desjardins A, Peters KB et al. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. J Neurooncol 2012;107:155-164.
10. Kreisl TN, Zhang W, Odia Y et al. A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro Oncol 2011;13: 1143-1150.
11. Vredenburgh JJ, Desjardins A, Herndon JE II et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007; 13:1253-1259.
12. Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740-745.
13. Lai A, Filka E, McGibbon B et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: Interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 2008;71:1372-1380.
14. Gilbert MR, Sulman EP, Mehta MP. Bevacizumabfor newly diagnosed glioblastoma.NEngl JMed 2014;370:2048-2049.
15. Chinot OL, Wick W, Cloughesy T. Bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014;370:2049.
16. Odia Y, Shih JH, Kreisl TN et al. Bevacizumabrelated toxicities in the National Cancer Institute malignant glioma trial cohort. J Neurooncol 2014; 120:431-440.
17. Taal W, Oosterkamp HM, Walenkamp AM et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma(BELOB trial):A randomised controlled phase 2 trial. Lancet Oncol 2014;15:943-953.
18. Ranpura V, Pulipati B, Chu D et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: A meta-analysis. Am J Hypertens 2010;23:460-468.
19. Burger RA, Brady MF, Bookman MA et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365:2473-2483.
20. Zhu X, Wu S, Dahut WL et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis. Am J Kidney Dis 2007;49:186-193.
21. Maitland ML, Bakris GL, Black HR et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010;102:596-604.
22. Wu S, Kim C, Baer L et al. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 2010;21:1381-1389.
23. Gurevich F, Perazella MA. Renal effects of antiangiogenesis therapy: Update for the internist.AmJ Med 2009;122:322-328.
24. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358:1129-1136.
25. Sugimoto H, Hamano Y, Charytan D et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003;278:12605-12608.
26. Armstrong TS, Wen PY, Gilbert MR et al. Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors. Neuro Oncol 2012;14:1203-1214.
27. Velander AJ, DeAngelis LM, Navi BB. Intracranial hemorrhage in patients with cancer. Curr Atheroscler Rep 2012;14:373-381.
28. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: A meta-analysis. Lancet Oncol 2009; 10:559-568.
29. Higa GM, Abraham J. Biological mechanisms of bevacizumab-associated adverse events. Expert Rev Anticancer Ther 2009;9:999-1007.
30. Semrad TJ, O’Donnell R, Wun T et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 2007;106:601-608.
31. Brandes AA, Scelzi E, Salmistraro G et al. Incidence of risk of thromboembolism during treatment high-grade gliomas: A prospective study. Eur J Cancer 1997;33:1592-1596.
32. Zangari M, Fink LM, Elice F et al. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 2009;27:4865-4873.
33. Nalluri SR, Chu D, Keresztes R et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A metaanalysis. JAMA 2008;300:2277-2285.
34. Bombeli T, Karsan A, Tait JF et al. Apoptotic vascular endothelial cells become procoagulant. Blood 1997;89:2429-2442.
35. Wen PY, Schiff D, Kesari S et al. Medical management of patients with brain tumors. J Neurooncol 2006;80:313-332.
36. Nghiemphu PL, Green RM, Pope WB et al. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol 2008;10:355-360.
37. Norden AD, Bartolomeo J, Tanaka S et al. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. J Neurooncol 2012;106: 121-125.
38. Randall LM, Monk BJ. Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol 2010;117:497-504.
39. Scappaticci FA, Skillings JR, Holden SN et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99: 1232-1239.
40. Reinhold HS, Calvo W, Hopewell JW et al. Development of blood vessel-related radiation damage in the fimbria of the central nervous system. Int J Radiat Oncol Biol Phys 1990;18:37-42.
41. Girardi F, Franceschi E, Brandes AA. Cardiovascular safety of VEGF-targeting therapies: Current evidence and handling strategies. The Oncologist 2010;15:683-694.
42. Hapani S, Sher A, Chu D et al. Increased risk of serious hemorrhage with bevacizumab in cancer patients: A meta-analysis. Oncology 2010;79:27-38.
43. Cannistra SA, Matulonis UA, Penson RT et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:5180-5186.
44. Sliesoraitis S, Tawfik B. Bevacizumab-induced bowel perforation. J AmOsteopath Assoc 2011;111: 437-441.
45. Roodhart JM, Langenberg MH, Witteveen E et al.The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol 2008;3:132-143.
46. Kamba T, Tam BYY, Hashizume H et al. VEGFdependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006;290:H560-H576.
47. Tursi A. Advances in the management of colonic diverticulitis. CMAJ 2012;184:1470-1476.
48. Martin ST, Stocchi L. New and emerging treatments for the prevention of recurrent diverticulitis. Clin Exp Gastroenterol 2011;4: 203-212.
49. Narum S, Westergren T, Klemp M. Corticosteroids and risk of gastrointestinal bleeding: A systematic review and meta-analysis. BMJ Open 2014;4:e004587.
50. Seet RC, Rabinstein AA. Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment. QJM 2012;105:69-75.
51. Vredenburgh JJ, Cloughesy T, Samant M et al. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. The Oncologist 2010;15:1329-1334.
52. Brandes AA, Mason W, Pichler J et al. Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy? Future Oncol 2014;10:1137-1145.
53. Chi AS, Chamberlain MC. Is there a role for bevacizumab in the treatment of glioblastoma? The Oncologist 2013;18:1080-1082.